NCT00161642View on ClinicalTrials.gov

Study Evaluating CMD-193 in Advanced Malignant Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Neoplasms
Interventions
DRUG

CMD-193

Trial Locations (3)

19111

Philadelphia

37203

Nashville

03756

Lebanon

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00161642 - Study Evaluating CMD-193 in Advanced Malignant Solid Tumors | Biotech Hunter | Biotech Hunter